SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Howard who wrote (86)9/11/1997 1:12:00 AM
From: Eduardo Canto   of 569
 
Howard,
As of my last reading of the published data on the use of HA for osteoarthritis, there was no evidence to suggest that higher molecular weight works better than lower molecular weight HA or crosslinked HA. While it is enticing to think that higher molecular weight or crosslinked HA (such as Synvisc) would be more benefitial due to its viscoelastic properties, this is only theory and it has not been proven. It could just as well be that the HA injected into a joint must be natural HA non crosslinked to be able to enter the joint cartilage and provide more cushioning. There are no trials that I know of comparing low versus high molecular weight or crosslinked HA. I suspect that the therapeutic effect of HA is independent of its molecular weight to a great extent.

Regards,

E.C.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News